Cipher Net Income From Continuing Ops from 2010 to 2026
| CPH Stock | CAD 14.51 0.30 2.03% |
Net Income From Continuing Ops | First Reported 2016-12-31 | Previous Quarter 5.9 M | Current Value 5.5 M | Quarterly Volatility 4.3 M |
Check Cipher Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cipher Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 4.9 M, Interest Expense of 506.9 K or Selling General Administrative of 8.8 M, as well as many indicators such as Price To Sales Ratio of 14.31, Dividend Yield of 0.0458 or PTB Ratio of 5.25. Cipher financial statements analysis is a perfect complement when working with Cipher Pharmaceuticals Valuation or Volatility modules.
Cipher | Net Income From Continuing Ops |
Evaluating Cipher Pharmaceuticals's Net Income From Continuing Ops across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Cipher Pharmaceuticals's fundamental strength.
Latest Cipher Pharmaceuticals' Net Income From Continuing Ops Growth Pattern
Below is the plot of the Net Income From Continuing Ops of Cipher Pharmaceuticals over the last few years. It is Cipher Pharmaceuticals' Net Income From Continuing Ops historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Cipher Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Net Income From Continuing Ops | 10 Years Trend |
|
Net Income From Continuing Ops |
| Timeline |
Cipher Net Income From Continuing Ops Regression Statistics
| Arithmetic Mean | 11,072,615 | |
| Coefficient Of Variation | 142.90 | |
| Mean Deviation | 10,685,672 | |
| Median | 11,545,000 | |
| Standard Deviation | 15,822,798 | |
| Sample Variance | 250.4T | |
| Range | 65.8M | |
| R-Value | (0.15) | |
| Mean Square Error | 261.2T | |
| R-Squared | 0.02 | |
| Significance | 0.57 | |
| Slope | (464,277) | |
| Total Sum of Squares | 4005.8T |
Cipher Net Income From Continuing Ops History
About Cipher Pharmaceuticals Financial Statements
Cipher Pharmaceuticals investors utilize fundamental indicators, such as Net Income From Continuing Ops, to predict how Cipher Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Net Income From Continuing Ops | 13.3 M | 8.4 M |
Other Information on Investing in Cipher Stock
Cipher Pharmaceuticals financial ratios help investors to determine whether Cipher Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Cipher with respect to the benefits of owning Cipher Pharmaceuticals security.